Although payers argue copay accumulator programs are only intended to shift patients to less expensive generic alternatives, a new survey conducted by MME Advisors found that the majority of pharmacy and medical directors representing various health plans nationwide strongly agree that copay accumulator programs can shift costs from plan sponsors to patients. Most also agreed that copay accumulator programs could negatively impact patient’s adherence to their medication, and one in four payers strongly agreed that copay accumulator programs could discourage appropriate utilization of specialty therapies. Payers also reported the biggest barriers to copay accumulator programs were pushback from members/patients, program design, potential medication disruption, and legal and operational barriers. Despite these barriers, payers expect an increase in copay accumulator programs in the future. Read the survey results here.
Last Updated on February 8, 2021 by Aimed Alliance
